Tissue-agnostic cancer drug

Tissue-agnostic cancer drugs are antineoplastic drugs that treat cancers based on the mutations that they display, instead of the tissue type in which they appear.^[1][2][3] Tissue-agnostic drugs that have been approved for medical use include Pembrolizumab, Larotrectinib, Selpercatinib, Entrectinib, and Pralsetinib.^[2][4][5][6]

History

Pembrolizumab was approved by the US Food and Drug Administration in May 2017.^[7]

Larotrectinib was approved by the FDA in November, 2018.^[7]

Selpercatinib (LOXO-292) received priority review in September 2018^[7] and was approved for medical use in the United States in May 2020.^[8][9]

Entrectinib was approved for medical use in the United States in August 2019,^[10][11] in Australia in May 2020,^[12] and in the European Union in July 2020.^[13]

Pralsetinib was approved for medical use in the United States in September 2020.^[14][15]

Dabrafenib and trametinib have been approved as tissue-agnostic drugs for solid tumors that are B-RAF positive. ^[16]

Tissue-agnostic cancer drugs that are under development as of May 2022^[update] include Selitrectinib (Loxo-195) and anti-ERBB3 antibodies.^[7]